INS and type 1 diabetes mellitus: Thus, in a double-blind,placebo-controlled study including 46 type 1 diabetes patients, with an averageage of 29 years and approximately 10 years of diabetes duration, and with reducedsensory nerve and motor nerve conduction velocities (NCV) but no other signs ofneuropathy, C-peptide replacement (1.8 mg/day) or placebo was given for 3 months together with thepatients' regular insulin therapy [19].